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Abstract: Deregulation of intracellular signal transduction pathways is a hallmark of cancer
cells, clearly differentiating them from healthy cells. Differential intracellular distribution of the
cAMP-dependent protein kinases (PKA) was previously detected in cell cultures and in vivo
in glioblastoma and medulloblastoma. Our goal is to extend this observation to meningioma, to explore
possible differences among tumors of different origins and prospective outcomes. The distribution
of regulatory and catalytic subunits of PKA has been examined in tissue specimens obtained during
surgery from meningioma patients. PKA RI subunit appeared more evenly distributed throughout
the cytoplasm, but it was clearly detectable only in some tumors. RII was present in discrete spots,
presumably at high local concentration; these aggregates could also be visualized under equilibrium
binding conditions with fluorescent 8-substituted cAMP analogues, at variance with normal brain
tissue and other brain tumors. The PKA catalytic subunit showed exactly overlapping pattern to
RII and in fixed sections could be visualized by fluorescent cAMP analogues. Gene expression
analysis showed that the PKA catalytic subunit revealed a significant correlation pattern with genes
involved in meningioma. Hence, meningioma patients show a distinctive distribution pattern of PKA
regulatory and catalytic subunits, different from glioblastoma, medulloblastoma, and healthy brain
tissue. These observations raise the possibility of exploiting the PKA intracellular pathway as
a diagnostic tool and possible therapeutic interventions.
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1. Introduction
Meningiomas comprise the largest number of central nervous system (CNS) tumors, accounting
for more than one-third of all CNS tumors, with a female:male ratio of about 2:1 [1]. Despite their
number, meningiomas are much less studied compared to other tumors, presumably because of their
less aggressive phenotype, unlike the most aggressive glioblastoma (GBM). Presumably, meningioma
originates from arachnoidal cap cells located along venous sinuses. The recent 2016 World Health
Organization classification of CNS tumors did not revise the classification of 16 existing meningioma
entities, except for the inclusion of invasiveness as a diagnostic criterion for Grade II atypical
meningioma [2], while for other CNS tumors, molecular characterization has been included in the
diagnostic criteria. Deregulation of signal transduction mechanisms can be detected in almost all tumor
cells, and aberrant signal transduction mechanisms involved in cytoskeleton regulation are presumably
present in many meningiomas. In this sense, meningiomas may prove to be of interest because of the
involvement of Merlin, a protein encoded by the NF2 gene, which is mutated or lost in roughly one half
of meningioma patients [3]. Merlin, also known as schwannomin, is apparently devoid of any catalytic
or DNA binding activity, but is presumably involved in cytoskeleton dynamics, by binding actin,
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and in cell shape control, contributing to contact-dependent inhibition of proliferation [4]. As expected,
this tumor suppressor protein interacts extensively with many signal transduction mechanisms,
including the cyclic adenosine-monophosphate (cAMP) pathway; noticeably, it can also function as an
A-kinase anchoring protein [5,6].
The cAMP-dependent signalling cascade acts mainly through cAMP dependent protein kinases
(PKA) that are tetramers of two regulatory (that is, they bind cAMP) and two catalytic subunits, which
may phosphorylate target proteins upon binding of two molecules of cAMP to each regulatory subunit,
resulting in the release of catalytic subunits [7]. Four regulatory isoforms have been characterized
in mammalian cells. According to cell types and functional conditions, these regulatory isoforms
are differently expressed. Inside cells, regulatory isoforms can be partly diffusible and partly bound,
mainly through PKA anchoring proteins called AKAPs, to cytoskeleton or intracellular organelles [8].
Differential expression as well as the ratio of the regulatory subunits of PKA RI/RII are important [9],
since a high amount of RI has been detected in certain types of aggressive tumors [10]. Specifically,
in the case of merlin, cAMP-dependent phosphorylation can greatly modify the behaviour of this
oncosuppressor protein [11].
We have previously described the distribution of detergent-insoluble regulatory subunits of PKA
in normal brain and found that it changes during brain development and in different disease models.
The four regulatory subunits (RIAlpha, RIBeta, RIIAlpha, and RIIBeta) are expressed in different
brain areas and even if present in the same cell, they are apparently located at different intracellular
sites [12–14]. Interestingly, in different human brain tumors, we found different patterns of PKA
distribution [15–17], supporting the idea that dysregulation of the cAMP pathway may serve as
a diagnostic tool as well as a potentially druggable target [18,19].
The distribution of the regulatory and catalytic subunits has been examined in meningioma
histological sections by immunofluorescence and fluorescent cAMP equilibrium binding, to unravel
differences in comparison to the previously examined tumors. We also explored a gene expression
database to highlight the correlation between PKA subunit or the expression of other genes involved
in meningioma. The data presented here show a different pattern of distribution of PKA regulatory and
catalytic subunits, compared to previously observed tumors. These data suggest a possible difference
in biochemical activity due to different, never observed, cAMP-binding properties, compared to both
normal brain and other brain tumors.
2. Results
2.1. Meningioma Tissue Binds cAMP
Meningioma specimens were obtained at surgery (see Table S1) and were examined via
immunofluorescence to reveal the presence of regulatory and catalytic subunits of PKA, followed by
equilibrium binding of fluorescently-tagged 8-derivatives of cAMP. Representative images are shown
in the figures and Supplementary Material. The conditions for optimal immunofluorescence were set
on frozen samples: a mild fixation followed by permeabilization gave optimal results for PKA catalytic
immunofluorescence (see Figure S1). However, all samples were examined with the different fixation
protocols, and blind as concerns specific diagnosis, because diagnosis was not available at the time
of examination. Under the same conditions, it was possible to observe labelling with fluorescent-tagged
cAMP, which was due to specific cAMP binding, since it was completely abolished by the competitor
non-fluorescent molecule 8Br-cAMP (Figure S2). The fluorescent cAMP labelling is not due to fixation
artefacts, since it was present also in the unfixed tumor; see Figure S3, which shows another specimen,
labelled with cAMP coupled to different fluorophores: similar results were obtained with fluorescein-,
Alexa 488-, Alexa 555-, and rhodamine-tagged cAMP (see Materials and Methods), with diverse
brightness due to different quantum yield of the fluorophores. The same structures were not labelled
by another cyclic nucleotide, the fluorescein-tagged cGMP. In any case, the binding appears to be
facilitated by washing or permeabilization, suggesting that it involves binding to insoluble structures.
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2.2. PKA Regulatory and Catalytic Subunits Immunofluorescence
In all meningioma samples, PKA RII immunofluorescence revealed strong punctuated labelling,
apparently located outside the cell nuclei, as shown by DAPI nuclear counterstaining (Figures 1 and 2 A–C).
Figure 1. Case 2, meningioma with sclerosis areas. (A): PKA RII immunofluorescence. (B) Same
photographic field, nuclei are labelled with DAPI. (C) Merge of (A) and (B). (D) Negative control,
omission of primary antibody in an adjacent section (incubation with only secondary antibody,
red-labelled) results in no red signals. Unaltered images. A and D taken with the same filters setting
and same exposure time from adjacent sections. Objective: 40x. Bar = 25 µm.
Figure 2. Cont.
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Figure 2. Case 3 representative images. (A) PKA RII immunofluorescence. (B) Same field, DAPI nuclear
counterstaining. (C) Merging of (A) and (B). (D) Low power image of PKA RII immunofluorescence.
(E) Same field, SAF-cAMP labelling. (F) Merging of (D) and (E); the orange color indicates coincidence
of the red and green signals. (G) Percentage of colocalization (blue) or non-colocalization (green) of cAMP
with PKA RII, relative to Figure 2 (F). (H) Percentage of colocalization (blue) or non-colocalization (red)
of PKA RII with cAMP, relative to Figure 2 (F). (A–C): 100x objective, bar = 10 µm. (D–F): 20x objective,
bar = 50 µm. Unaltered images.
After PKA RII immunofluorescence, incubation with fluorescent cAMP showed a nearly complete
coincidence of the two signals (Figure 2 D–F): this condition was not observed previously in the
normal brain or in other types of tumors. The lack of colocalization of fluorescent cAMP with PKA RI
was surprising, since fluorescent cAMP-RI colocalized in the healthy brain tissue and also in other
tumors, while in meningioma fluorescent cAMP mostly colocalized with PKA catalytic and RII subunit
(see Figure 3 and Figure S4, which shows the original single-channel figures).
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Figure 3. Case 5 representative images. (A) Merging of PKA RI immunofluorescence (red) and
SAF-cAMP labelling (green): the signals are clearly separated (see original single channel images
in Figure S4A,B). (B) Percentage of colocalization (blue) or non-colocalization (green) of cAMP with
PKA RI, relative to Figure 3A. (C) Percentage of colocalization (blue) or non-colocalization (red)
of PKA RI with cAMP, relative to Figure 3A. (D) Merging of PKA RII immunofluorescence (red) and
SAF-cAMP labelling (green): the signals coincide as shown by the yellowish labelling (see original
single channel images in Figure S4C,D). (E) Percentage of colocalization (blue) or non-colocalization
(green) of cAMP with PKA RII, relative to Figure 3D. (F) Percentage of colocalization (blue) or
non-colocalization (red) of PKA RII with cAMP, relative to Figure 3D. (G) Merging of PKA catalytic
subunit immunofluorescence (red) and SAF-cAMP labelling (green): the signals coincide, as shown
by the orange-yellowish color (see original single channel images in Figure S4E,F). (H) Percentage
of colocalization (blue) or non-colocalization (green) of cAMP with PKA catalytic subunit (CAT), relative
to Figure 3G. (I) Percentage of colocalization (blue) or non-colocalization (red) of PKA catalytic subunit
with cAMP, relative to Figure 3G. 100x objective, bar = 10 µm. Unaltered images.
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2.3. PKA RI is Extremely Labile in Meningioma
Another peculiarity of RI labelling in meningioma is its extreme lability, being present only in fixed
but not permeabilized tissue. For both brain and other tumors processed in the same experimental
session (for example, case 19 in reference [17], which was run with meningioma case 3), PKA RI
immunolabelling was found to be present and colocalized with fluorescent cAMP, but not with PKA
RII; moreover, both fluorescent cAMP and immunolabelling could be observed in permeabilized tissue.
On the contrary, in the present series of meningioma samples, PKA RI immunolabelling was sensitive
to permeabilization, disappearing in conditions in which fixation is followed by permeabilization,
suggesting that PKA RI was present as a soluble pool. This inference is supported by preliminary
observations of protein expression and partitioning in two cases, in which RI was detected in the
soluble pool, while RII was present in the insoluble fraction, and CAT was present in both soluble and
insoluble fractions (see Figure S5). To note, permeabilization does not affect fluorescent cAMP labelling,
which appears to co-localize with both PKA RII and catalytic subunits, a condition not observed
in healthy tissue or other tumors. A summary of the results obtained from immunofluorescence and
equilibrium binding is presented in Table 1.
Table 1. Summary of results obtained with the fixation protocol that gives optimal results for each
antigen. The intensity of equilibrium binding was evaluated in the best labelled immunofluorescent
sections. Grading is a mean of values obtained in different repetitions of the experiment by two
observers that independently scored the slides. IF: immunofluorescence. NA: not available, slices lost
during processing. Grading: −: negative. −/+: some positive trials, some negative. +: faint labelling.
++: moderate. +++: intense labelling. The relative intensity was evaluated for each case.
CASE N◦ cAMP Equilibrium Binding PKA RI IF PKA RII IF PKA CATALYTIC IF
1 + + Mostly on vessels +++ +++
2 +/− Only in some zones + +++ Only in some zones +++ Only in some zones
3 +++ + +++ +++
4 ++ + +++ +++
5 ++ ++ ++ ++
6 + + ++ ++
7 + NA NA ++
8 ++ + +++ +++
9 - + ++ Only in some zones ++ Only in some zones
10 + + Only in some zones +++ +++
11 +/− - +++ +++
12 +++ + +++ +++
13 +++ - +++ +++
2.4. Correlation of PKA Catalytic Subunit Expression Levels with Different Gene Products
Next, a database reporting the expression level of different genes in 68 meningioma cases was
interrogated with BioGPS (see Material and Methods for details) to explore the relationship between
PRKACA gene, coding for PKA CAT, and PKA regulatory subunits (PRKAR1A, PRKAR1B, PRKAR2A,
and PRKAR2B) gene products. The expression level of PRKACA is positively, yet not significantly,
correlated with PRKAR1B, PRKAR2A, and PRKAR2B (Pearson’s R = 0.1199, 0.1937 and 0.1659,
respectively), while a significant negative correlation was detected between PRKAR1A and PRKACA
(Pearson’s R = -0.2547, p < 0.05); see Figure 4.
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Figure 4. Gene expression of PKA catalytic and regulatory subunits in a cohort of 68 meningioma
patients. (A) Gene expression level for PRKACA, PRKAR1A, PRKAR1B, PRKAR2A, and PRKAR2B.
(B) Comparative view of the correlation between PRKACA expression and the four genes coding for the
PKA regulatory subunits. (C–F) Correlation of the expression of PRKACA with each of the single genes
for PKA regulatory subunits shown in (B). (C) A significant negative correlation is present between
PRKACA and PRKAR1A expression, while weak, non-significant correlations are present between
PRKACA and PRKAR1B (D), PRKAR2A (E), and PRKAR2B (F).
Meningioma patients often present a loss of chromosome 22q, with inactivating neurofibromin2
(NF2, the gene coding for merlin) mutations in monosomic 22 specimens: NF2 expression level is
positively and significantly correlated with PRKACA expression (R = 0.2994, p < 0.05), suggesting
that both genes are downregulated in meningioma. Conversely, NF2 expression does not correlate
significantly with any of the four PKA regulatory subunits expression levels (Table 2).
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Table 2. Correlation of PRKA subunits’ gene expression levels with meningioma-related genes (Pearson’s R
values. Significant correlations are in bold and marked by * p < 0.05, ** p < 0.02, *** p < 0.005).
PRKACA PRKAR1A PRKAR1B PRKAR2A PRKAR2B
NF2 0.2994 ** 0.0679 −0.0406 0.0965 0.1524
CDC2 −0.2973 ** 0.0518 −0.0246 0.1128 −0.3763 ***
MLF1IP −0.2908 ** 0.0363 −0.0844 0.2692 * −0.3098 **
CKS2 −0.3188 ** −0.1402 −0.1074 0.0945 −0.3754 ***
PRC1 −0.3622 *** −0.0497 −0.0640 0.1630 −0.3563 ***
Subsequently, we focused on the four genes that are differentially over-expressed in recurrent
meningioma: cell division cycle protein 2 homolog (CDC2, which codes for Cyclin-dependent kinase
1, CDK1), MLF1IP coding for Centromere Protein U (CENPU), Cyclin-dependent kinases regulatory
subunit 2 (CKS2), and Protein Regulator of cytokinesis 1 (PRC1). The expression of all of these genes is
significantly correlated in an inverse manner with PRKACA and PRKAR2B. There is only a slight yet
significant positive correlation between MLF1IP and PRKAR2A expression (Table 2).
Lastly, we clustered the patients according to their status (dead N = 10 vs. alive N = 57, N = 1
patient status not determined), assuming that the dead patients had more aggressive tumors. However,
no significant difference was detected between alive and dead patients in the expression levels for
either PKA catalytic or regulatory subunits (Figure 5A), nor for the five recurrent meningioma-related
proteins (Figure 5B).
Figure 5. Expression levels of different genes in patients still alive or dead at the end of the study.
(A) The expression level of the PKA regulatory and catalytic genes does not differ between dead and
alive patients. (B) The expression level of five meningioma-related genes does not differ between dead
and alive patients. Log10 axes.
3. Discussion
The cAMP signalling system acts mainly through PKA, which are present in all cells to mediate
multiple information pathways, mainly through the expression of specific regulatory and catalytic
subunits and through docking at precise subcellular locations. Regulatory subunits of PKA form
homodimers, contributing to the specificity of the signalling system. We described the localization of the
docked pool of the regulatory subunits of PKA in the brain of tetrapods, along with the changes that
take place during ontogenetic development in the brain of mammals, birds, and reptiles [12–14,20–22],
showing that homolog brain areas present a similar PKA distribution, related to cell type and
developmental stage. This distribution may change in animal models of disease, like Parkinson’s
disease and depression [23,24]. By using fluorescently-tagged cAMP, we observed that, while in vitro
these molecules could bind to each form of soluble PKA regulatory subunit [25], in brain histological
sections they could bind only to PKA RIAlpha [26], suggesting that the supramolecular organization
of PKA docking complexes hindered the access of fluorescent molecules to PKA RII but not to RIAlpha.
This also holds true for the brain of different species. Different issues were explored for tumors. In rodent
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and human glioma cells, we described a cluster of PKA RII localized in Golgi apparatus that could
be targeted, resulting in apoptosis of tumor cells [15]. These data were further confirmed in a series
of glioblastoma specimens in comparison to other 17 specimens of different tumors and grade [17],
in which PKA RII was the most prominent labelling, with scarce, if any, PKA RI. In glioblastoma,
fluorescent cAMP labelling was almost undetectable, with only scarce and sporadic labelling. A series
of medulloblastoma was also examined: in this tumor, we observed the first deviation from PKA
RI/fluorescent cAMP coincidence, normally found in the brain. In medulloblastoma, fluorescent cAMP
labelled numerous structures that partly coincided with PKA catalytic subunit, but not with either PKA
RI and RII, offering a new scenario for cAMP signalling within this tumor [16]. In the present work,
we hypothesized that the PKA signalling pathways could be affected, since data from the literature
highlight the cAMP system as a possible crossroad of many intracellular pathways.
Meningiomas have received much less attention than other CNS tumors due to their relative benign
nature, despite being the most frequent intracranial tumors [4]; however, nearly 20% of meningiomas
recur, without any clear molecular fingerprint for transformation, besides the common chromosome 22q
loss, leading to NF2 inactivation [27]. At present, the WHO classification reports several meningioma
subtypes, mainly pertaining to Grade I and three each to Grade II and III, based on histological appearance,
without indicating molecular markers. A recent classification was proposed by a multicentric team based
on genome-wide DNA methylation pattern for patient stratification [28]. Roughly 20% of meningiomas
do not present obvious genetic alteration, while the most common genetic alteration is the inactivation
of the NF2 gene coding for the protein Merlin. Usually, meningiomas present activation of receptors for
multiple growth factors and their downstream signalling [29], with PDGF-beta overexpression driving
malignant transformation in mice meningiomas [30]. However, several other pathways may be involved;
for example, dysregulation of the MAPK signalling pathway [31,32], in particular, the p38 MAPK [33], or S6
kinase [34], or recently found mutations in in TRAF7, AKT1, KLF4, SMO, and PIK3CA [35], suggesting
the use of targeted kinase inhibitors and immunotherapies [36]. At present, maximal surgical resection
and radiation are the gold standard therapies, with alpha-interferon, VEGF inhibitors, and somatostatin
receptor agonists used in recurrent meningiomas [37].
The cyclic AMP pathway is involved in the development of different brain tumors. Progression
in some tumors may be linked to hyperactivation of the GalphaS pathway, which activates the
PKA signalling, which in turn negatively regulates the Hippo pathway through blockade of the
NF2-LAT-Yap signalling [38]. The involvement of the WNT signalling pathway has been recently
recognized in meningiomas [39], with the WNT-coupled transcription factor FOXM1 being a key
marker for aggressive meningiomas [40]; to note, the WNT pathway communicates with the G protein
coupled receptor/PKA pathway to modulate beta-catenin phosphorylation and beta-catenin-dependent
transcription [41].
As in other brain tumors, meningiomas also presented a higher level of the cAMP-degrading
enzyme phosphodiesterase 4A [42], suggesting that targeting this pathway could be a feasible option
for the clinical management of recurrent meningiomas. This idea is supported by microarray expression
data, showing differential expression of phosphodiesterase 1C in different grade meningiomas [43].
Phosphodiesterases are also involved in tumorigenesis in Neurofibromatosis type 1 (NF1) models [44],
and phosphodiesterase 5 blockade has resulted in breast cancer stem cell elimination through the
activation of PKA [45]. By analysing the kinome and phosphoproteomic profiles of meningioma
of different grades, it was recently shown that the A-kinase anchoring protein 12, a docking protein
for PKA RII, was downregulated according to increasing malignancy grade, by comparing Grades II
and III to Grade I meningiomas; this highlights AKAP12 as a prognostic marker for invasiveness and
a central regulator in meningioma [46]. Another meningioma series reports significant upregulation
of AKAP12 and phospho-AKAP12 in Grade I and II meningiomas compared to meningeal tissue, while
a non-significant increase is reported for Grade III meningiomas [47]; in any case, the involvement
of AKAP12 seems warranted. The relationships between the regulatory type RI and RII with AKAP12
will be explored in our future works. Meningioma cells were demonstrated to react to cAMP or
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cAMP-elevating agents with a decrease in cell growth rate, an effect partly mediated via the secretion
of interleukin 6, which acts as an inhibitory factor [48]. On the contrary, increase of cell growth may be
induced by somatostatin, since meningiomas mostly express somatostatin receptors that repress the
formation of cAMP [49]. Interestingly, amplification of the long arm of chromosome 17 was found
in anaplastic meningiomas, in proximity of the locus hosting PRKAR1A gene, encoding for PKA
RIAlpha, suggesting a possible link to its expression [50].
Prompted by the differences in the localization of PKA catalytic and regulatory subunits, we explored
the gene expression profile of a series of meningioma patients, to reveal possible relationships between
the PKA isoforms and other genes specifically affected in meningioma. At variance with the normal brain
and the malignant brain tumor glioblastoma (see Figure S1A in [17] for a comparison), in meningioma,
PRKAR1A appears the most expressed PKA regulatory isoform. This is also supported by a proteomic
study comparing different grade meningiomas to normal meninges [47], which reports a significant
increase in non-phosphorylated RI for Grade II and III meningiomas and in phosphorylated RI for all
grades, together with increases in phosphorylated proteins RIIA, RIIB, and CAT in Grade III. Interestingly,
recurrent mutation in PRKAR1A has been reported in few meningioma cases with non-mutated NF2
gene [51]. As shown in the present data, the distribution of RI in meningiomas is different from what can
be appreciated in the brain or in other tumors like glioblastoma or medulloblastoma [16,17]. Noteworthy,
PRKAR1A is the only regulatory subunit gene whose expression correlates significantly, albeit negatively,
with PKA catalytic subunits. This observation suggests that PRKACA expression may be negatively
regulated in meningioma. The positive correlation of PRKACA with NF2 gene expression [27], which is
downregulated in meningioma, may support this view, as well as the negative correlation of PRKACA
expression with the four upregulated genes typically found in recurrent meningiomas (CDC2, MLF1IP,
CKS2, and PRC1) [27]. These data prompt further analysis and validation with protein quantification,
because of a possible non-linearity in protein translation or subsequent modifications in the protein
itself or in protein turnover.
Our present data add another piece to the biomolecular characterization of meningioma, further
supporting the centrality of the cAMP signalling pathway in the development of these tumors. Here, we
show that the meningioma tissue presents organization of PKA that has different features from what can
be observed in healthy brain or different tumors of the brain of different origin, like medulloblastoma
and glioblastoma. In particular, PKA RI appears mostly present in soluble form, besides being the
most expressed PKA regulatory subunit. The coincidence of fluorescent cAMP labelling with PKA RII
and catalytic subunits suggest a different supramolecular organization that could be exploitable as
a possible therapeutic target. Moreover, the use of fluorescent cAMP labelling could be of interest for
diagnostic purposes during surgery, given that it also works in few minutes in unfixed tissue. Hence,
the present data highlight three molecular properties (e.g. RI lability, CAT/RII colocalization, and RII
binding cAMP 8-derivatives in situ) that could not be predicted or demonstrated by other approaches.
4. Materials and Methods
4.1. Patients
This study was performed according to the 1964 Declaration of Helsinki and its later amendments.
It conformed to Italian legislation and was approved by the institutional Ethical Committee
(Comitato Etico per la Sperimentazione — Azienda Ospedaliera di Padova protocol number 1883P). Patients
(see Table S1 for details) gave their written informed consent and were recruited at the University
of Padova Medical School. During surgery for tumor removal, one fragment of the tumor tissue
was excised and immediately frozen by dipping in liquid nitrogen. Tissues were stored at −70 ◦C
until sectioning.
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4.2. Tissue Processing
The chemicals were from Sigma (Milan, Italy), unless otherwise stated. Immunofluorescence and
equilibrium binding protocols conform to previously published methods [16,17]. Tissues were cut
on a cryostat at 20 µm. Serial sections were air dried and fixed with four different protocols: (1) Mild
fixation, 1 minute in formalin 5% in phosphate-buffered saline (PBS) at 37◦C; (2) mild fixation followed
by permeabilization, 1 minute in formalin 5% at 37◦C then 30’ in Triton X-100 2% in PBS; (3) formalin
5% 1 hour at room temperature, then Triton X-100 2% 30’; and (4) Triton X-100 2% 30’, then formalin 5%
1’ at 37◦C. The primary antibodies were incubated overnight. The following antibodies were used [15]:
Anti PKA RIIA (Santa Cruz Biotechnology, cross-reactive for both RII alpha and beta isoforms) 1:200;
Anti PKA RIB (Santa Cruz Biotechnology, cross-reactive for both RI alpha and beta isoforms) 1:200;
and Anti PKA catalytic subunit 1:200 (Santa Cruz Biotechnology, cross-reactive for all isoforms).
Secondary antibody (1:200 on tissue) was incubated for 30 min at 37◦C: anti-rabbit IgG Alexafluor
594-conjugate (Molecular Probes-Invitrogen, Milan, Italy), or anti-rabbit IgG fluorescein-conjugate
(Sigma, Milan, Italy). Cell nuclei were counterstained with DAPI (Sigma, Milan, Italy). Positive and
negative controls were included in each staining session: positive controls were mouse brain sections,
whose labeling pattern is known [12–14]; negative controls were processed omitting the primary
antibody, or incubated with normal rabbit serum.
For the colocalization experiments, some sections were incubated for 10 minutes at
room temperature in PBS containing one of the following fluorescent nucleotides: 300 nM
8-(5-thioacet amidofluorescein)-adenosine 3’,5’-cyclic monophosphate (SAF-cAMP), or with 300 nM
8-(5-thioacetamidofluorescein)-guanosin 3’,5’-cyclic monophosphate (SAF-cGMP) or with 8-(5-thioacet
amidotetramethylrhodamine)-adenosine 3’,5’-cyclic monophosphate (SAR-cAMP), or with 250 nM
8-(2-fluoresceinylthioureidoaminoethylthio)-adenosine 3’,5’ -cyclic monophosphate (8-Fluo-cAMP), or
with 100 nM 8-(Alexa488)- adenosine 3’,5’-cyclic monophosphate (Alexa488-cAMP) or 8-(Alexa555)-
adenosine 3’,5’-cyclic monophosphate (Alexa555-cAMP), as previously described [26]. SAF-cAMP,
SAF-cGMP, and SAR-cAMP were synthesized [52], Alexa488-cAMP and Alexa 555-cAMP were from
Molecular Probes (Eugene, OR), 8-Fluo-cAMP was obtained from BioLog (Germany). They are all
readily displaced by 50 µM 8-Br-cAMP, resulting in specific abolition of the fluorescent cAMP labelling
(see Figure S1). After immunofluorescence, the sections were counterstained with hematoxylin–eosin.
4.3. Image Analysis
Slides were observed with a Leica epifluorescence microscope (20×, 40×, and 100× objectives).
Immunofluorescence and equilibrium binding labelling was independently graded during observation
at the microscope by two observers on a semiquantitative scale. Images were acquired with the resident
software at 768 × 582 pixels with an RGB color digital camera, using the same parameters within each
experiment. The images were used unaltered, unless otherwise stated. They were superimposed
using Graphic Converter 9 and set up in Powerpoint 16.16.6. For determining colocalization, images
were analyzed with ImageJ software. Each image was split on the three channels and the maxima
(pixels intensity at least 10 AU above adjacent background) were marked and counted, then red and
green images were superimposed, and the maxima were evaluated as being superimposed (if they
were coincidental) or not, in order to obtain the number of green only, red only, and coincidental
maxima, from which the percentage was calculated.
4.4. Expression Data Analysis
Data obtained with Affymetrix U133 Plus 2.0 expression arrays from 68 meningioma patients
(age range 32-89 years, both genders), initially reported in [27] were interrogated with BioGPS
(www.biogps.org) [53–55]. Histograms were generated and expression levels was correlated with
Pearson’s R statistic, while expression levels between dead and alive patients were compared with
T-test using R software. Significant level was set at p < 0.05.
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5. Conclusions
Meningioma has no clear molecular landmarks. Despite presenting few mutations, some data
indicate that the cAMP pathway may be involved in dysregulated growth of meningioma cells. Here,
we found that PKA regulatory subunits are distributed differently in meningioma, compared to
a healthy brain and other tumors, and present a different cAMP-binding activity, which may be
of interest for therapeutic or diagnostic purposes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/11/1686/s1.
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Henegariu, O.; et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1,
and SMO. Science 2013, 339, 1077–1080. [CrossRef]
36. Gupta, S.; Bi, W.L.; Dunn, I.F. Medical management of meningioma in the era of precision medicine.
Neurosurg. Focus 2018, 44, E3. [CrossRef]
37. Karsy, M.; Guan, J.; Cohen, A.; Colman, H.; Jensen, R.L. Medical Management of Meningiomas: Current
Status, Failed Treatments, and Promising Horizons. Neurosurg. Clin. N. Am. 2016, 27, 249–260. [CrossRef]
38. Warrington, N.M.; Sun, T.; Rubin, J.B. Targeting brain tumor cAMP: The case for sex-specific therapeutics.
Front. Pharmacol. 2015, 6, 153. [CrossRef]
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